For example, in lung adenocarcinoma patients with KRAS mutations, applying treatments with MEK, ERK, or SHP2 inhibitors had better outcomes than standard treatment targeting EGFR38. This evidence concerns the gene MAP2K7 and lung adenocarcinoma.